Plant Health Care has more than doubled its H1 pretax loss to $6.6m, from a loss of $3.0m. Revenue was $2.9m, from $3.2m.
"During the first six months of 2016, we have made further solid progress in building the sales momentum of Commercial Products; trading conditions have recently become increasingly challenging and we expect headwinds in the second half, with continuing revenue growth anticipated in 2017," said executive chair Christopher Richards.
"We are also making great strides in the development of our PREtec New Technology. With the completion of the $10 million placement in August 2016, we are now confident of delivering first revenues from our PREtec peptide platforms and of bringing our Commercial business to profit, within our existing cash resources."